• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腮腺肿瘤术后三维适形放疗中声学结构剂量分布的前瞻性研究:剂量学和听力学方面。

Prospective study on the dose distribution to the acoustic structures during postoperative 3D conformal radiotherapy for parotid tumors: dosimetric and audiometric aspects.

机构信息

Division of Radiotherapy, European Institute of Oncology, Milan, Italy.

出版信息

Strahlenther Onkol. 2011 Jun;187(6):350-6. doi: 10.1007/s00066-011-2170-5. Epub 2011 May 16.

DOI:10.1007/s00066-011-2170-5
PMID:21603994
Abstract

BACKGROUND AND PURPOSE

To analyze dose distribution in the hearing organ and to evaluate the dose effect on the hearing thresholds in patients treated with post-parotidectomy 3-dimensional conformal radiotherapy (3D-CRT).

METHODS AND MATERIALS

A total of 17 patients received post-parotidectomy 3D-CRT (median dose: 63 Gy). The audiometric evaluation comprised pure tone audiometry and tympanometry performed before radiotherapy (RT) and 3, 6, and 24 months after RT. The ear structures were delineated on planning computer tomography scans. Mean and maximum doses were calculated and dose-volume histograms were plotted.

RESULTS

Before RT, the median baseline audiometric thresholds were normal. At 3 months post-RT, 3 patients were diagnosed as having middle ear underpressure and/or effusion that resolved completely by 6 months. During 2-year follow-up, none of the ears showed perceptive hearing loss at speech frequencies. The mean doses at ipsilateral external auditory canal, mastoids cells, tympanic case, Eustachian tube, semicircular canals, and cochlea were 44.8 Gy, 39.0 Gy, 30.9 Gy, 33.0 Gy, 19.6 Gy, and 19.2 Gy, respectively. The doses to the contralateral ear were negligible, except for the Eustachian tube (up to 28.2 Gy).

CONCLUSION

Post-parotidectomy 3D-CRT is associated with relatively low doses to the ear and the surrounding structures. Post-RT audiometry did not show any permanent (neither conductive nor perceptive) hearing impairment. Only in 3 patients were there signs of transient unilateral dysfunction of the Eustachian tube observed during the first few months after RT. Longer follow-up and larger patient series are warranted to confirm these preliminary findings.

摘要

背景与目的

分析听器官的剂量分布,并评估接受腮腺切除术后三维适形放疗(3D-CRT)的患者的听力阈值的剂量效应。

方法与材料

共 17 例患者接受腮腺切除术后 3D-CRT(中位剂量:63 Gy)。听力评估包括放疗前(RT)和 RT 后 3、6 和 24 个月的纯音听力和鼓室压图。在计划计算机断层扫描上勾画耳部结构。计算平均剂量和最大剂量,并绘制剂量-体积直方图。

结果

RT 前,中位基线听力阈值正常。RT 后 3 个月,3 例患者被诊断为中耳负压和/或积液,6 个月完全缓解。在 2 年随访期间,没有一只耳朵出现言语频率的感知性听力损失。同侧外耳道、乳突细胞、鼓膜、咽鼓管、半规管和耳蜗的平均剂量分别为 44.8 Gy、39.0 Gy、30.9 Gy、33.0 Gy、19.6 Gy 和 19.2 Gy。对侧耳的剂量可忽略不计,除了咽鼓管(高达 28.2 Gy)。

结论

腮腺切除术后 3D-CRT 与耳部和周围结构的相对低剂量相关。RT 后听力测试未显示任何永久性(既不是传导性也不是感知性)听力损伤。只有 3 例患者在 RT 后最初几个月观察到单侧咽鼓管短暂功能障碍的迹象。需要更长时间的随访和更大的患者系列来证实这些初步发现。

相似文献

1
Prospective study on the dose distribution to the acoustic structures during postoperative 3D conformal radiotherapy for parotid tumors: dosimetric and audiometric aspects.腮腺肿瘤术后三维适形放疗中声学结构剂量分布的前瞻性研究:剂量学和听力学方面。
Strahlenther Onkol. 2011 Jun;187(6):350-6. doi: 10.1007/s00066-011-2170-5. Epub 2011 May 16.
2
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients.头颈部癌症患者内耳辐射剂量与听力损失的前瞻性研究。
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1393-402. doi: 10.1016/j.ijrobp.2004.08.019.
3
Intensity-modulated vs. conformal radiotherapy of parotid gland tumors: potential impact on hearing loss.腮腺肿瘤的调强放疗与适形放疗:对听力损失的潜在影响
Med Dosim. 2007 Winter;32(4):237-45. doi: 10.1016/j.meddos.2006.12.004.
4
Permanent unilateral hearing loss after radiotherapy for parotid gland tumors.腮腺肿瘤放疗后永久性单侧听力丧失。
Head Neck. 2006 Oct;28(10):902-8. doi: 10.1002/hed.20426.
5
Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.鼻咽癌调强放射治疗:与传统计划相比的剂量学优势及剂量递增的可行性
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):145-57. doi: 10.1016/s0360-3016(03)00075-0.
6
Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.局部晚期(II期及更严重)头颈癌的三维适形放疗:剂量学和临床评估
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1036-43. doi: 10.1016/j.ijrobp.2006.03.014. Epub 2006 Jun 5.
7
[Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].[头颈部癌患者唾液腺功能的定量和定性研究:依赖于照射剂量和体积以减少口干症]
Strahlenther Onkol. 2005 Aug;181(8):520-8. doi: 10.1007/s00066-005-1366-y.
8
Late effects of radiotherapy on hearing.
Eur Arch Otorhinolaryngol. 1992;249(6):305-8. doi: 10.1007/BF00179377.
9
Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease.肝细胞癌合并放射性肝病患者三维适形放疗与调强放疗的剂量学分析与比较
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):229-34. doi: 10.1016/s0360-3016(03)00091-9.
10
Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.不可切除的非小细胞肺癌治疗中降低毒性和增加剂量的潜力:调强放射治疗(IMRT)、三维适形放疗和选择性淋巴结照射的比较
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):875-90. doi: 10.1016/s0360-3016(03)00743-0.

引用本文的文献

1
Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma.保留耳蜗的鼻咽癌优化放疗。
Radiat Oncol. 2021 Apr 1;16(1):64. doi: 10.1186/s13014-021-01796-4.
2
Melatonin reduces radiation damage in inner ear.褪黑素可减轻内耳辐射损伤。
J Radiat Res. 2021 Mar 10;62(2):217-225. doi: 10.1093/jrr/rraa137.
3
Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports.基于 QUANTEC 报告发布之后的头颈部标准分割放射治疗相关正常组织并发症模型的系统评价

本文引用的文献

1
Brachial plexopathy after chemoradiotherapy for head and neck squamous cell carcinoma.臂丛神经病:头颈部鳞癌放化疗后的并发症。
Strahlenther Onkol. 2010 Sep;186(9):517-20. doi: 10.1007/s00066-010-2099-0. Epub 2010 Aug 30.
2
A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma.一项针对中 T 期口咽癌单纯改变分割调强放疗的 I/II 期研究。
Strahlenther Onkol. 2010 Sep;186(9):489-95. doi: 10.1007/s00066-010-2093-6. Epub 2010 Aug 30.
3
Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol.
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):391-407. doi: 10.1016/j.ijrobp.2017.09.041. Epub 2017 Sep 29.
4
Radiotherapy for vestibular schwannoma: Review of recent literature results.前庭神经鞘瘤的放射治疗:近期文献结果综述
Rep Pract Oncol Radiother. 2016 Jul-Aug;21(4):399-406. doi: 10.1016/j.rpor.2016.02.002. Epub 2016 Feb 28.
5
Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics.质子放疗与传统放疗用于小儿涎腺肿瘤:急性毒性和剂量学特征
Radiother Oncol. 2015 Aug;116(2):309-15. doi: 10.1016/j.radonc.2015.07.022. Epub 2015 Jul 28.
复发性头颈部鳞状细胞癌的交替多西紫杉醇为基础的化疗再放疗:单中心前瞻性二期方案的更新。
Strahlenther Onkol. 2010 May;186(5):255-61. doi: 10.1007/s00066-010-2082-9. Epub 2010 Apr 26.
4
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.局部晚期、不可手术的头颈部癌症患者行原发放化疗后出现高级别急性器官毒性可作为一个阳性预后因素。
Strahlenther Onkol. 2010 May;186(5):262-8. doi: 10.1007/s00066-010-2136-z. Epub 2010 Apr 26.
5
Radiation therapy and hearing loss.放射治疗与听力损失。
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S50-7. doi: 10.1016/j.ijrobp.2009.04.096.
6
Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.单纯顺铂与顺铂+5-氟尿嘧啶用于局部晚期不可切除的IV期头颈部鳞状细胞癌的放化疗对比研究
Strahlenther Onkol. 2009 Oct;185(10):675-81. doi: 10.1007/s00066-009-1992-x. Epub 2009 Oct 6.
7
Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.局部晚期头颈癌患者接受手术联合放(化)疗或根治性放(化)疗后,对预后因素和两种放疗技术的评估
Strahlenther Onkol. 2008 Apr;184(4):198-205. doi: 10.1007/s00066-008-1825-3.
8
Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.螺旋断层放射治疗。海德堡首批150例患者的经验。
Strahlenther Onkol. 2008 Jan;184(1):8-14. doi: 10.1007/s00066-008-1778-6.
9
Otological toxicity after postoperative radiotherapy for parotid tumours.腮腺肿瘤术后放疗后的耳毒性
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):77-82. doi: 10.1016/j.clon.2006.11.007.
10
Ototoxicity after radiotherapy for head and neck tumors.头颈部肿瘤放疗后的耳毒性
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):469-79. doi: 10.1016/j.ijrobp.2006.09.017.